Impact of poor-quality medicines in the 'developing' world
about
The primacy of public health considerations in defining poor quality medicinesCombating poor-quality anti-malarial medicines: a call to actionTowards the just and sustainable use of antibioticsA poor-quality generic drug for the treatment of visceral leishmaniasis: a case report and appealQuality of antimalarial drugs and antibiotics in Papua New Guinea: a survey of the health facility supply chainResponding to the pandemic of falsified medicines.Coupling laser ablation/desorption electrospray ionization to atmospheric pressure drift tube ion mobility spectrometry for the screening of antimalarial drug quality.Public health measures to fight counterfeit medicine market.Erroneous formulation of delayed-release omeprazole capsules: alert for importing countriesAnti-malarial medicine quality field studies and surveys: a systematic review of screening technologies used and reporting of findings.A call for using natural compounds in the development of new antimalarial treatments - an introduction.Innovation in regulation of rapidly changing health marketsDerivative Technology of DNA Barcoding (Nucleotide Signature and SNP Double Peak Methods) Detects Adulterants and Substitution in Chinese Patent Medicines.Organised crime and the efforts to combat it: a concern for public health.Soil-transmitted helminths in pre-school-aged and school-aged children in an urban slum: a cross-sectional study of prevalence, distribution, and associated exposures.An exploration of counterfeit medicine surveillance strategies guided by geospatial analysis: lessons learned from counterfeit Avastin detection in the US drug supply chain.Prevalence estimates of substandard drugs in Mongolia using a random sample survey.A need for the standardization of the pharmaceutical sector in Libya.Paper analytical devices for fast field screening of beta lactam antibiotics and antituberculosis pharmaceuticals.Effects of packaging and storage conditions on the quality of amoxicillin-clavulanic acid - an analysis of Cambodian samples.Current scenario of spurious and substandard medicines in India: a systematic review.Enabling the Development and Deployment of Next Generation Point-of-Care DiagnosticsQuality of antimalarials at the epicenter of antimalarial drug resistance: results from an overt and mystery client survey in Cambodia.Quality of the antibiotics--amoxicillin and co-trimoxazole from Ghana, Nigeria, and the United Kingdom.Counterfeit drug penetration into global legitimate medicine supply chains: a global assessmentSubstandard antimalarials available in Afghanistan: a case for assessing the quality of drugs in resource poor settings.Malaria eradication and elimination: views on how to translate a vision into realityThe impact of a novel franchise clinic network on access to medicines and vaccinations in Kenya: a cross-sectional study.Poor quality drugs: grand challenges in high throughput detection, countrywide sampling, and forensics in developing countries.Elixirs of death. International organizations are working towards a global solution to address the problem of falsified and substandard medicines, but progress has stagnated.Substandard and counterfeit medicines: a systematic review of the literature.Falsified antimalarials: a minireview.After counterfeit Avastin®--what have we learned and what can be done?Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies.Estimated under-five deaths associated with poor-quality antimalarials in sub-Saharan Africa.In vitro dissolution of generic immediate-release solid oral dosage forms containing BCS class I drugs: comparative assessment of metronidazole, zidovudine, and amoxicillin versus relevant comparator pharmaceutical products in South Africa and IndiaPredictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpointWhat does the growing prominence of Asia mean for pharmaceutical safety management?Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.
P2860
Q21563004-03C1E0AB-5F08-4D96-82DF-A69BBB1395B6Q24658634-6B7E4C8C-E3BD-48AB-9B10-11C67E9A81DBQ28067846-ADA165A9-0215-4168-8576-213440F27CFEQ28483975-865659D2-FE62-4DE4-927B-BFD1CC0141F3Q28538830-7819C2B0-BEC9-4298-8642-4E632FD4EE1FQ30062161-1A667A9D-C2AD-4EA4-BFDC-2F78D1AB92A4Q33454558-B9D7A8A1-359C-431E-9065-E0C8E71D7BFCQ33600920-BA166F9E-F0EA-4945-A93B-054D40EBFF19Q33634731-06D0EBD6-C1F1-45E3-9913-78E22F3E0C95Q33691830-C96DEB36-C900-4510-80A3-8253C77D840AQ33848637-88E7134E-83B4-400D-AC8E-E65A4CF953EAQ33898030-E11E53A8-5593-4D47-9FEB-544706B77023Q33918890-8295616D-F2F2-4432-94FB-75CAA241E501Q34375396-A27275C8-78AD-4D08-96A3-BED4AC710301Q34496054-D7ACD524-18B9-4B70-BA5A-962A52D30246Q34635245-D8DB8DC4-70CA-43E8-B9D9-A7369FE0A8D1Q34697207-78283088-6A2B-434C-AFF6-D7B8323DB216Q34736310-5D6DE2BD-CA31-493D-8474-9CF28BEA07B8Q34750498-FFC2CDF2-AB5A-49AD-9C38-B6152C6933D8Q34774942-7E906F00-8BDD-41CD-8839-93B721167553Q35166222-C9DDEFA0-8418-4CE4-8069-B135A337C03EQ35606872-5BB6114D-E4A8-437A-AB0A-1BB3DFC82A9EQ35681778-257FC09B-7E53-4F18-9DC5-26EB3CA05618Q35681789-5DADD242-E655-428B-B6F1-8D253294F045Q35681817-8ECAC7ED-C56C-4D8C-8F77-287D91F69EE2Q35681822-A8FE5545-6A7F-43D4-B2BF-2ABA1C5C8F15Q35712522-0152D095-E382-49FB-A7B4-E4926788AB4EQ36103806-5390BC9E-A803-4113-B64A-FDA33D14B261Q36187038-7543158C-F770-4DEE-B440-9BCF809993F0Q36981895-77612606-7E50-46CF-AC45-D945FE5652ADQ37117268-AA266A20-86C3-45BD-A41D-8BAC3E6AA96BQ38356412-D2966A0C-F130-48DD-A42D-3E85D583FB6EQ38367161-45440F3F-54B9-4EC4-BF2F-58236B7E142AQ38603812-BA38C743-D532-49C6-A89E-0EF3826ED8ABQ38867438-7154BBA4-126B-4776-95E7-9845A638EA2FQ39393283-46C90389-F926-48D7-A7E0-B0E401AAD065Q41987760-78057246-B25C-4632-99E1-5966B2B557A7Q42329781-5CB84F27-3258-4FC7-8300-F5A6A69698F7Q43632749-9AD70A09-707F-4791-B326-C9C38CCFA232Q46380663-F64A5CE4-85A3-4947-BE59-D0510B4DAB39
P2860
Impact of poor-quality medicines in the 'developing' world
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Impact of poor-quality medicines in the 'developing' world
@ast
Impact of poor-quality medicines in the 'developing' world
@en
type
label
Impact of poor-quality medicines in the 'developing' world
@ast
Impact of poor-quality medicines in the 'developing' world
@en
prefLabel
Impact of poor-quality medicines in the 'developing' world
@ast
Impact of poor-quality medicines in the 'developing' world
@en
P2093
P2860
P1476
Impact of poor-quality medicines in the 'developing' world
@en
P2093
Facundo M Fernández
Michael D Green
Paul N Newton
P2860
P304
P356
10.1016/J.TIPS.2009.11.005
P577
2010-02-01T00:00:00Z